Pharvaris (PHVS) Research & Development (2020 - 2026)

Pharvaris (PHVS) has 7 years of Research & Development data on file, last reported at -$35.3 million in Q1 2026.

• Quarterly Research & Development fell 8.59% year-over-year to -$35.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$76.4 million (down 10.18% YoY) and the FY2025 annual result came in at -$140.6 million, down 31.83% from the prior year.
• Research & Development rose to -$35.3 million in Q1 2026, from -$39.7 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $121.1 million in Q4 2023 to a low of -$39.7 million in Q4 2025.
• A 5-year average of $1.3 million and a median of -$15.2 million in 2022 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2022 — Research & Development soared 250.83% — and 2024, when it slumped 127.53%.
• Tracing PHVS's Research & Development over 5 years: stood at $100.7 million in 2022, then climbed by 20.24% to $121.1 million in 2023, then plunged by 127.53% to -$33.3 million in 2024, then dropped by 19.2% to -$39.7 million in 2025, then rose by 11.15% to -$35.3 million in 2026.
• The last three Research & Development figures came in at -$35.3 million (Q1 2026), -$39.7 million (Q4 2025), and -$34.9 million (Q3 2025), per Business Quant data.